Thursday 13 June 2019

The Brewery, London EC1


2017 Voting Panel



Read bio

(Voting Panel Chairman) 

Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding Design Portfolio in 1991, he has been active in helping hundreds of companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society. 



Read bio

Vadim has over a decade of capital markets experience, specialising in the healthcare sector. He currently runs the Research department at Northland Capital Partners, where he established a leading healthcare franchise. Previously he headed the Research department at Daniel Stewart & Co., where he also established a healthcare franchise for the firm. Prior to that, he worked in research and healthcare analysis roles for Economic and Business Data Inc. and Healthcare Information Technologies Inc. Vadim holds a BSc in Microbiology and Immunology and a Master’s degree in Economics from McGill University. 

Chris Golden


Read bio

Chris has twelve years of corporate finance experience, advising healthcare & life sciences companies. He joined Peel Hunt in 2016 and previously held responsibility for healthcare & life sciences at Cenkos Securities. Prior to Cenkos, Chris advised healthcare & life sciences companies at Nomura Code and SG Cowen. Before joining the City, Chris held research positions at Merck KGaA and Sharp Laboratories of Europe. Chris has a PhD in organic chemistry.



Read bio

Max joined Stifel in September 2013 as Head of European Healthcare Equity Research. Prior to this he was Chief Financial Officer of Silence Therapeutics plc. Max possesses more than 20 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development-stage companies, as well as establishing several highly rated equity research teams at a number of investment banks. 

Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Account with Arthur Andersen.



Read bio

David is a Fund Manager at Polar Capital, responsible for the biotechnology fund, and has over 16 years of investment experience in healthcare, specialising in biotechnology. He has managed investments across both venture and specialist funds for firms including SV Life Sciences, Abingworth and Morgan Stanley. David holds a first class honours degree in Human Sciences from the University of Oxford and is a CFA Charterholder.  



Read bio

Nick is an experienced non-executive director and chairman with a background as a successful corporate financier. He has considerable experience of businesses in the healthcare, medical, biotechnology, environmental and technology industries. 

Until February 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Nick is also chairman of SEHTA, one of the largest health technology networking organisations in the UK. Until March 2013, Nick was the Chief Executive of Ipso Ventures plc, a creator of, and an investor in, early-stage technology and healthcare businesses. In this capacity he has created eight businesses around university technology.



Read bio

Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 18 years’ experience in life sciences research, covering both UK and continental European companies across a wide range of healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services across both large and small-cap companies. Prior to Canaccord Genuity, Julie was a member of the No.1 Extel-rated Healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Life Sciences Research. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early-stage medical technologies. 



Read bio

Melanie is a Partner, Life Sciences at Instinctif Partners and she leads on financial communications within the Life Sciences team. She has 20 years of experience advising life sciences companies on financial communications. Prior to joining Instinctif Partners, she built and established the life sciences practice at the Hogarth Partnership. She was a Partner in the Financial Dynamics (now FTI) Life Sciences team and a Director at Merlin Financial PR. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare industries, as well as advising specialist VC and IP commercialisation companies. Before entering business communications, she was at Price Waterhouse where she qualified as a Chartered Accountant. She has a BA in Biochemistry from the University of Oxford. 

Mike Ward

Informa Pharma Intelligence

Read bio

Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. He is currently Global Director of Content for Informa’s Pharma Insights business, which includes the flagship products Scrip and Pink Sheet. In 2005, Nature Biotechnology identified Mike as one of the most influential people in European biotech. In 2010 he was named European Mediscience Media Commentator of the Year and he has appeared on the shortlist for that award on other occasions. In 2016, he was identified by Labiotech.Eu as “one of the 13 biotech leaders you should know in the golden triangle”. 


Positive Capital Partners

Read bio

Renee is a Managing Partner of Positive Capital Partners and was previously a Partner and COO of Omega Funds. Before Omega, she served as a Partner in the Venture Capital group 3i Group plc in London where, since 2005, she was responsible for managing their publicly quoted assets and European legacy healthcare portfolio. In addition, whilst at 3i, Renee structured and executed several secondary sale processes. Prior to this, she was a European Group Head and MD in investment banking. Renee has over twelve years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on raising M&A and private and public capital for growth companies in both Europe and the US. Prior to investment banking, Renee worked for five years in European sales and marketing for a financial services-focused software business. Renee has a BA in Finance from Stockholm School of Economics and an MBA from INSEAD. She has significant Board experience from both private and public Board work and is presently a Board member of Scibase AB, Simparel Inc and EnXray Limited.  



Read bio

Amber is a Healthcare Communications Specialist and co-founder of Consilium Strategic Communications. Amber has extensive experience in providing strategic communications support to some of the healthcare sector’s leading companies and has delivered successful PR campaigns, including significant sector IPOs, M&A, and public and private fundraisings, across Europe and North America. Prior to founding Consilium, Amber was a member of M:Communications’ Healthcare team and the Pharma & Biotech team at Citigate Dewe Rogerson. Amber also has a strong background in public affairs and lobbying, with experience from the European Parliament in Brussels, the United States Senate in Washington, DC, and work for the UK’s BioIndustry Association. Amber has a degree in International History and Politics from the University of Leeds and a Master’s degree in War Studies from King’s College London. 



Read bio

Anne joined MC Services in 2011. Prior to this, she held senior management positions in international pharma and biotech companies. Most recently she headed the Investor Relations and Corporate Communications department of Evotec AG for ten years and was a member of the Company’s Executive Committee. Previously, she was responsible for investor relations and corporate communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing department. 

Anne has 20 years’ experience in financial and strategic communications. During her career she has managed Evotec’s IPO on the Frankfurt Stock Exchange and NASDAQ, multiple M&A programmes, and major financial transactions. Anne is a pharmacist and marketing expert by training.



Read bio

Tony is Director of Business Development at One Nucleus. After completing a PhD in Biochemistry at the University of Southampton in 1992, Tony undertook several years of post-doctoral research in the oncology field, primarily with the Imperial Cancer Research Fund (now CRUK). In 1997, he moved into technology transfer with the Medical Research Council and later (1998) University College London, at the Wolfson Institute for Biomedical Research. 

In November 2003, Tony took up the post of Director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network and the promotion of London’s excellence in healthcare research and delivery. In May 2010, he took the London Biotechnology Network into the merger with ERBI, seeing this as the best manner in which to continue assisting member companies develop their businesses. 

His role at One Nucleus encompasses the development of the membership offer to reflect the current external environment and changing needs placed upon members’ businesses. He leads on delivery of the BioWednesday events series and the annual Genesis Conference.



Read bio

Tara has a BSc in Biochemistry and a PhD in Structural Biology, both from Imperial College London. She worked with the top-ranked European Healthcare Equity Research team at Lehman Brothers/Nomura. She then moved to Jefferies, where she spent several years as part of the European Biotechnology and Life Sciences Equity Research team. Prior to her role as the Healthcare Analyst at Shore Capital, Tara set up her own life sciences consultancy. 



Read bio

Jonathan was previously a Biotech Equity Research Analyst at Credit Suisse (where his team was ranked number one by Institutional Investor) and Evolution. Prior to joining Stifel, he spent six years in corporate finance at Nomura Code. Jonathan’s fundraising experience includes NicOx, GPC Biotech, Actelion, Carmat, Vernalis, Glide Pharma, Ergomed and Rex Bionics. His M&A experience includes the sales of CeNeS, CBT Pharmaceuticals, Biocompatibles International and Protherics. Jonathan is a qualified medical doctor. 


Third Eye Healthcare Fund

Read bio

Sachin is the promoter, co-founder and Fund Manager of Third Eye. Prior to incorporating Third Eye in 2016, Sachin worked as an Equity Research Analyst on the Life Sciences team in the Securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands, before becoming a Director and Head of the Life Sciences team. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European healthcare and life sciences sector and won Extel and Starmine awards for stock picking. He has over ten years of experience in life sciences, with an exposure to both private (Venture Capital) as well as public market investments, and has been involved in multiple IPOs and secondary transactions, raising over €1.0bn for various life sciences companies. 


Zeus Capital

Read bio

Gary is an experienced healthcare analyst having worked in the City since early 2001. He joined Zeus Capital in January 2014 and is responsible for research coverage of life sciences, including companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has worked on numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Nomura Code and KBC Peel Hunt. Prior to becoming an analyst, he managed an R&D group at a Canadian biotech company and before that he was a Postdoctoral Fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. His academic training includes an MBA from the University of Durham Business School and a PhD in Immunology from the Faculty of Medicine at Monash University (Melbourne, Australia), where he also obtained a BSc.